310 related articles for article (PubMed ID: 23450552)
1. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD004434. PubMed ID: 23450552
[TBL] [Abstract][Full Text] [Related]
2. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2009 Jul; (3):CD004434. PubMed ID: 19588356
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J
Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
[TBL] [Abstract][Full Text] [Related]
5. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Cheng J
Cochrane Database Syst Rev; 2005 Jan; (1):CD004434. PubMed ID: 15674947
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
7. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Guanylate cyclase stimulators for pulmonary hypertension.
Wardle AJ; Seager MJ; Wardle R; Tulloh RM; Gibbs JS
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011205. PubMed ID: 27482837
[TBL] [Abstract][Full Text] [Related]
10. Prostacyclin for pulmonary hypertension in adults.
Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002994. PubMed ID: 15846646
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
12. Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants.
More K; Athalye-Jape GK; Rao SC; Patole SK
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010531. PubMed ID: 27535894
[TBL] [Abstract][Full Text] [Related]
13. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
14. Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
Widlitz AC; Barst RJ; Horn EM
Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):985-91. PubMed ID: 16292989
[TBL] [Abstract][Full Text] [Related]
15. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
Barst RJ; Langleben D; Badesch D; Frost A; Lawrence EC; Shapiro S; Naeije R; Galie N;
J Am Coll Cardiol; 2006 May; 47(10):2049-56. PubMed ID: 16697324
[TBL] [Abstract][Full Text] [Related]
16. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
Langleben D; Brock T; Dixon R; Barst R;
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S80-4. PubMed ID: 15838366
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.
Barst RJ; Rich S; Widlitz A; Horn EM; McLaughlin V; McFarlin J
Chest; 2002 Jun; 121(6):1860-8. PubMed ID: 12065350
[TBL] [Abstract][Full Text] [Related]
18. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
[TBL] [Abstract][Full Text] [Related]
19. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
[TBL] [Abstract][Full Text] [Related]
20. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension.
Benza RL; Gomberg-Maitland M; Demarco T; Frost AE; Torbicki A; Langleben D; Pulido T; Correa-Jaque P; Passineau MJ; Wiener HW; Tamari M; Hirota T; Kubo M; Tiwari HK
Am J Respir Crit Care Med; 2015 Dec; 192(11):1345-54. PubMed ID: 26252367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
